Xencor Inc
About Xencor Inc
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $125.6M
- Net income
- -$91.9M
- Total assets
- $875.5M
- Market cap
- $872.6M
- Operating margin
- -141.4%
- Net margin
- -73.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $125.6M
- Operating expenses
- $303.1M
- Operating income
- -$177.5M
- Income tax
- $2.5M
- Net income
- -$92.1M
- EPS (basic)
- $-1.24
- EPS (diluted)
- $-1.24
Balance sheet
- Total assets
- $875.5M
- Current assets
- $599.8M
- Total liabilities
- $239.9M
- Current liabilities
- $95.9M
- Shareholders’ equity
- $635.6M
Cash flow
- Operating cash flow
- -$135.1M
- Investing cash flow
- $140.0M
- Financing cash flow
- $8.2M
- Net cash flow
- $13.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $872.6M
- EPS (diluted)
- $-1.24
- Shares outstanding
- 76.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 3, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $91.9M in FY2025.
- Revenue grew 2% from FY2020 to FY2025.
- Trading 37% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xencor Inc.
Write a review
News about Xencor Inc
News & sentiment via Polygon.io
